Man Group PLC Ardelyx, Inc. Transaction History

Man Group PLC

$49.7 Billion
Q2 2025

A detailed history of Man Group PLC transactions in Ardelyx, Inc. stock. As of the latest transaction made, Man Group PLC holds 227,698 shares of ARDX stock, worth $1.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

227,698

Previous 121,845 86.88%

Holding current value

$1.2 Million

Previous $598,000 49.16%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$3.28 - $5.51 $347,197 - $583,250	105,853 Added 86.88%	227,698 $892,000
Q1 2025 May 15, 2025	BUY	$4.91 - $6.36 $598,258 - $774,934	121,845 New	121,845 $598,000
Q3 2022 Nov 14, 2022	SELL	$0.59 - $1.44 $4,301 - $10,499	-7,291 Reduced 35.02%	13,531 $16,000
Q2 2022 Aug 15, 2022	BUY	$0.51 - $1.17 $10,619 - $24,361	20,822 New	20,822 $12,000
Q4 2019 Feb 18, 2020	SELL	$4.23 - $8.29 $63,027 - $123,520	-14,900 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$2.15 - $6.28 $30,100 - $87,920	-14,000 Reduced 48.44%	14,900 $70,000
Q2 2019 Aug 14, 2019	SELL	$2.49 - $3.73 $277,137 - $415,149	-111,300 Reduced 79.39%	28,900 $78,000
Q1 2019 May 15, 2019	SELL	$1.88 - $3.35 $13,160 - $23,450	-7,000 Reduced 4.76%	140,200 $393,000
Q4 2018 Feb 14, 2019	SELL	$1.66 - $4.16 $65,072 - $163,072	-39,200 Reduced 21.03%	147,200 $263,000
Q3 2018 Nov 14, 2018	BUY	$3.75 - $4.65 $198,000 - $245,520	52,800 Added 39.52%	186,400 $811,000
Q2 2018 Aug 14, 2018	BUY	$3.7 - $5.8 $494,320 - $774,880	133,600 New	133,600 $494,000

Others Institutions Holding ARDX

# of Institutions

222

Shares Held

167M

Call Options Held

517K

Put Options Held

1.61M

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $816M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account